FDA Releases Guidance on Tobacco Product Warning Labels and Ads

Regulations by 2FIRSTS.ai
Sep.13.2024
FDA Releases Guidance on Tobacco Product Warning Labels and Ads
FDA issues new guidance on tobacco warning labels, following court challenges, with plans for enforcement in 2025.

On September 12th, the U.S. Food and Drug Administration (FDA) website announced that they are providing guidance on the final rule regarding "Tobacco Products; Required Warnings for Cigarette Packages and Advertisements." The rule aims to promote greater public understanding of the negative health effects of smoking by adding new health warnings to cigarette packaging and advertisements.


The final rule was published in March 2020 and faced a challenge in the Eastern District Court of Texas. In December 2022, the district court overturned the rule. However, the government appealed this decision, and in May 2024, the United States Fifth Circuit Court of Appeals overturned the district court's ruling, reinstating the final rule, which is now officially in effect. The plaintiffs are now waiting for review by the Supreme Court.


In the newly released guidance document, the FDA plans to exercise enforcement discretion for 15 months or until December 12, 2025, generally not enforcing the requirements of final rules. For products manufactured before December 12, 2025, the FDA will also provide an additional 30-day grace period, or until January 12, 2026. The FDA has chosen a 15-month orderly transition period, consistent with the initially envisioned 15-month compliance period of the Family Smoking Prevention and Tobacco Control Act, but impacted by litigation proceedings.


The final rule also requires the industry to submit plans and obtain FDA approval to ensure that warning labels on cigarette packaging are displayed and distributed randomly and evenly, while rotating warning labels on cigarette advertisements quarterly. Therefore, entities with cigarette health warning plans that have not yet been approved are advised to submit such plans as soon as possible, but must do so within five months or by February 10, 2025. Entities that had previously submitted cigarette plans to the FDA do not need to resubmit their plans unless they wish to make changes.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%
BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%
BAT Rothmans introduces "glo hyper" series promotion in South Korea, with "glo hyper pro" for $20 and "glo hyper" for $14.
Oct.15 by 2FIRSTS.ai
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian outlet Rebel News released a long-form video report examining Canada’s regulatory framework for nicotine pouches, market dynamics, and the approval process of ZONNIC, a product of BAT subsidiary Imperial Tobacco Canada. The report highlights issues involving youth access, regulatory gaps, black-market activity, retailer feedback, and company responses. This article summarizes key points based on the video.
Dec.02 by 2FIRSTS.ai
BAT accused of “utter hypocrisy” over efforts to dilute Zambia’s tobacco bill
BAT accused of “utter hypocrisy” over efforts to dilute Zambia’s tobacco bill
The Guardian reports that British American Tobacco urged Zambian ministers to drop or delay ad and sponsorship bans and to soften a draft tobacco bill by shrinking health warnings, easing flavour restrictions and lowering penalties. Critics said the stance is hypocritical given similar rules apply in the UK.
Nov.13
KT&G Nears ASF Acquisition, Preparing Wide Regional Nicotine Pouch Expansion
KT&G Nears ASF Acquisition, Preparing Wide Regional Nicotine Pouch Expansion
South Korean outlet nate reports that KT&G expects to finalize its acquisition of Nordic nicotine pouch maker ASF within this year. Beginning next year, the company plans to expand the business well beyond ASF’s current five Nordic markets to Europe, the Middle East, Africa, Asia and North America, supported by its cooperation framework with Altria.
Nov.25
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai
German Federal Council calls for ban on disposable vape, government resists change
German Federal Council calls for ban on disposable vape, government resists change
Germany's Federal Council calls for ban on disposable e-cigarettes due to environmental and economic threats, sparking debate.
Oct.14 by 2FIRSTS.ai